UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) April 4, 2005 (March 31, 2005)
PROTALEX, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 000-28385 | 91-2003490 |
| (Commission File Number) | (IRS Employer Identification No.) |
| 145 Union Square Drive, New Hope, PA | 18938 |
| (Address of Principal Executive Offices) | (Zip Code) |
215-862-9720
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8- Other Events
Item 8.01 Other Events.
Protalex, Inc. (the “Company”) filed an Investigative New Drug (IND) Application with the United States Food and Drug Administration (FDA) on March 4, 2005, as disclosed in our prior SEC filings. Based on the FDA’s review, the FDA has verbally disclosed to the Company that it has placed the Company’s IND on clinical hold effective March 31, 2005, pending additional product characterization.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protalex, Inc. (Registrant) | ||
| | | |
| Date:4/4/2005 | By: | /s/ Marc L. Rose |
By: Marc L. Rose | ||
Title: Vice President of Finance, Chief Financial Officer and Treasurer | ||